Interrogating open issues in cancer medicine with patient-derived xenografts.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

27 citing papers in PubMed.

1. Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers.ESMO open · 2020
   Trial
2. Biomimetic hydrogel for the construction of patient-derived bladder cancer organoids with aggressive growth.iScience · 2026
   Article
3. Navigating Cancer Treatment: A Journey from 2D to 3D Cancer Models and Nanoscale Therapies.ACS pharmacology & translational science · 2025
   Review
4. Organoid-based two-step drug screening for rapid identification of chemotherapy-resistant oesophageal squamous cell carcinoma and alternative therapies.Clinical and translational medicine · 2025
   Article
5. Prospects and challenges of ovarian cancer organoids in chemotherapy research (Review).Oncology letters · 2025
   Review
6. Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine.Life (Basel, Switzerland) · 2024
   Review
7. Capturing heterogeneity in PDX models: representation matters.Nature communications · 2024
   Article
8. Organoids derived from metastatic cancers: Present and future.Heliyon · 2024
   Review
9. Bibliometric analysis of global research on human organoids.Heliyon · 2024
   Article
10. Perivascular localized cells commit erythropoiesis in PDGF-B-expressing solid tumors.Cancer communications (London, England) · 2023
    Article
11. Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer.Journal of experimental & clinical cancer research : CR · 2022
    Article
12. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology.Nature cancer · 2022
    Article
13. Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations.Cancer cell · 2022
    Review
14. Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models.Frontiers in oncology · 2022
    Review
15. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer.Cell · 2021
    Article
16. Molecular phenotypes reveal heterogeneous engraftments of patient-derived hepatocellular carcinoma xenografts.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2021
    Article
17. Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cellsClinical & translational immunology · 2021
    Article
18. The ongoing trends of patient-derived xenograft models in oncology.Cancer communications (London, England) · 2020
    Article
19. Progress in the application of organoids to breast cancer research.Journal of cellular and molecular medicine · 2020
    Review
20. Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma.Cancers · 2019
    Article

Corrections and comments

• Erratum for
  Interrogating open issues in cancer precision medicine with patient-derived xenografts.2017

Authors and funding

42 authors.

Funding

Abstract